National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China.
BACKGROUND: Long-term use of antiplatelet agents, statins, beta-blockers and angiotensin-converting enzyme inhibitors are proven therapies for secondary prevention in acute coronary syndrome. However, little is known of physicians' opinion about their use in China. METHODS: In 2010, standard qu...
| Auteurs principaux: | , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
2013
|
| _version_ | 1826296910976122880 |
|---|---|
| author | Li, J Li, X Chen, Y Chen, Z Zhang, L Feng, F Zhang, H Liu, J Gao, Y Hundei, W Li, L Jiang, L |
| author_facet | Li, J Li, X Chen, Y Chen, Z Zhang, L Feng, F Zhang, H Liu, J Gao, Y Hundei, W Li, L Jiang, L |
| author_sort | Li, J |
| collection | OXFORD |
| description | BACKGROUND: Long-term use of antiplatelet agents, statins, beta-blockers and angiotensin-converting enzyme inhibitors are proven therapies for secondary prevention in acute coronary syndrome. However, little is known of physicians' opinion about their use in China. METHODS: In 2010, standard questionnaires were posted to chief cardiologists in 1397 geographically diverse and representative sample of tertiary and secondary hospitals in China, collecting information about their opinions on the recommended treatments for acute coronary syndrome. RESULTS: A total of 1009 (72%) cardiologists responded with a valid questionnaire. Of them, 77% reported routine use of all the four main secondary preventive treatments, with little difference between secondary and tertiary hospitals (75% vs. 79%, P = 0.16). Of the cardiologists reporting routine or selective use of aspirin, beta-blockers, statins and angiotensin-converting enzyme inhibitors, 94%, 85%, 73% and 86% would recommend indefinite use respectively. For all the 4 treatments combined, only 63.5% reported indefinite use at the same time, with no significant difference between secondary and tertiary hospitals (62% vs. 65%, P = 0.17), nor between hospitals with or without fast track for primary percutaneous coronary intervention (66% vs. 61%, P = 0.50). CONCLUSIONS: Although Chinese cardiologists seem well informed about the value of main secondary preventive treatments for acute coronary syndrome, there is still gap in their understanding of the need for combined and prolonged use of these treatments. |
| first_indexed | 2024-03-07T04:23:36Z |
| format | Journal article |
| id | oxford-uuid:cbdf8251-a4a3-43af-9284-49f892aea194 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:23:36Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:cbdf8251-a4a3-43af-9284-49f892aea1942022-03-27T07:17:46ZNational survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:cbdf8251-a4a3-43af-9284-49f892aea194EnglishSymplectic Elements at Oxford2013Li, JLi, XChen, YChen, ZZhang, LFeng, FZhang, HLiu, JGao, YHundei, WLi, LJiang, LBACKGROUND: Long-term use of antiplatelet agents, statins, beta-blockers and angiotensin-converting enzyme inhibitors are proven therapies for secondary prevention in acute coronary syndrome. However, little is known of physicians' opinion about their use in China. METHODS: In 2010, standard questionnaires were posted to chief cardiologists in 1397 geographically diverse and representative sample of tertiary and secondary hospitals in China, collecting information about their opinions on the recommended treatments for acute coronary syndrome. RESULTS: A total of 1009 (72%) cardiologists responded with a valid questionnaire. Of them, 77% reported routine use of all the four main secondary preventive treatments, with little difference between secondary and tertiary hospitals (75% vs. 79%, P = 0.16). Of the cardiologists reporting routine or selective use of aspirin, beta-blockers, statins and angiotensin-converting enzyme inhibitors, 94%, 85%, 73% and 86% would recommend indefinite use respectively. For all the 4 treatments combined, only 63.5% reported indefinite use at the same time, with no significant difference between secondary and tertiary hospitals (62% vs. 65%, P = 0.17), nor between hospitals with or without fast track for primary percutaneous coronary intervention (66% vs. 61%, P = 0.50). CONCLUSIONS: Although Chinese cardiologists seem well informed about the value of main secondary preventive treatments for acute coronary syndrome, there is still gap in their understanding of the need for combined and prolonged use of these treatments. |
| spellingShingle | Li, J Li, X Chen, Y Chen, Z Zhang, L Feng, F Zhang, H Liu, J Gao, Y Hundei, W Li, L Jiang, L National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China. |
| title | National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China. |
| title_full | National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China. |
| title_fullStr | National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China. |
| title_full_unstemmed | National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China. |
| title_short | National survey of doctor-reported secondary preventive treatment for patients with acute coronary syndrome in China. |
| title_sort | national survey of doctor reported secondary preventive treatment for patients with acute coronary syndrome in china |
| work_keys_str_mv | AT lij nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT lix nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT cheny nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT chenz nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT zhangl nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT fengf nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT zhangh nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT liuj nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT gaoy nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT hundeiw nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT lil nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina AT jiangl nationalsurveyofdoctorreportedsecondarypreventivetreatmentforpatientswithacutecoronarysyndromeinchina |